Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey, Hee Jung An, Seung-Ki Kim, et al.
International Journal of Cancer (2018) Vol. 145, Iss. 5, pp. 1179-1188
Open Access | Times Cited: 291

Showing 1-25 of 291 citing articles:

Exploiting senescence for the treatment of cancer
Liqin Wang, Lina Lankhorst, René Bernards
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 340-355
Open Access | Times Cited: 518
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Mónica Álvarez‐Fernández, Marcos Malumbres
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 514-529
Open Access | Times Cited: 283
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Concepción Sánchez‐Martínez, Marı́a José Lallena, Sonia Gutiérrez Sanfeliciano, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 20, pp. 126637-126637
Closed Access | Times Cited: 178
Cyclin D-CDK4/6 functions in cancer
Xueliang Gao, Gustavo Leone, Haizhen Wang
Advances in cancer research (2020), pp. 147-169
Closed Access | Times Cited: 157
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Amelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 146
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1404-1421.e11
Closed Access | Times Cited: 131
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 99
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
Ruoning Yang, Yueyi Li, Hang Wang, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 74
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 27
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Lin Zhu, Kaiqing Yang, Zhe Ren, et al.
Translational Oncology (2024) Vol. 44, pp. 101945-101945
Open Access | Times Cited: 18
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors
Zhengyan Kan, Ji Wen, Vinícius Bonato, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
Élodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 107
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey, Nahee Park, Kyung‐Soon Park, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3566-3566
Open Access | Times Cited: 100
The Breast Cancer Stem Cells Traits and Drug Resistance
Qinghui Zheng, Mengdi Zhang, Fangfang Zhou, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 89
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Mara Bonelli, Silvia La Monica, Claudia Fumarola, et al.
Biochemical Pharmacology (2019) Vol. 170, pp. 113676-113676
Closed Access | Times Cited: 86
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo, Paolo Chiodini, Maria Riemma, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6400-6400
Open Access | Times Cited: 85
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott Schoninger, Stacy W. Blain
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 1, pp. 3-12
Open Access | Times Cited: 79
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
Xi Jin, Li‐Ping Ge, Da‐Qiang Li, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 78
Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
Lindsey R. Pack, Leighton H. Daigh, Mingyu Chung, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 77
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Victoria Damerell, Michael S. Pepper, Sharon Prince
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 71
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
Jinyao Huang, Liang Zheng, Zicheng Sun, et al.
International Journal of Molecular Medicine (2022) Vol. 50, Iss. 4
Open Access | Times Cited: 66
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
Aditi S. Khatpe, Adedeji K. Adebayo, Christopher Herodotou, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 369-369
Open Access | Times Cited: 61
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
Zijie Cai, Jingru Wang, Yudong Li, et al.
Science China Life Sciences (2022) Vol. 66, Iss. 1, pp. 94-109
Closed Access | Times Cited: 61
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
Yuan Yuan, Jin Sun Lee, Susan E. Yost, et al.
European Journal of Cancer (2021) Vol. 154, pp. 11-20
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top